NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity

被引:176
作者
Albertsson, PA [1 ]
Basse, PH
Hokland, M
Goldfarb, RH
Nagelkerke, JF
Nannmark, U
Kuppen, PJK
机构
[1] Sahlgrens Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden
[2] Univ Pittsburgh, Inst Canc, BST, Pittsburgh, PA 15213 USA
[3] Aarhus Univ, Inst Med Microbiol & Immunol, DK-8000 Aarhus, Denmark
[4] Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA
[5] Sopher Therapeut, New Haven, CT 06511 USA
[6] Leiden Univ, Div Toxicol, Leiden Amsterdam Ctr Drug Res, NL-2300 RA Leiden, Netherlands
[7] Univ Gothenburg, Fac Med, Inst Anat & Cell Biol, S-40530 Gothenburg, Sweden
[8] Leiden Univ, Ctr Med, Dept Surg, NL-2300 RC Leiden, Netherlands
关键词
D O I
10.1016/j.it.2003.09.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although it is clear that natural killer (NK) cells have the ability to recognize and kill tumour cells in vitro, their potential as a highly effective treatment for tumours has not yet been realized in the clinical setting. Following activation, endogenous and adoptively transferred NK cells can be found in tumours. However, not all tumours are equally well-infiltrated, and many of the infiltrating cells do not make target-cell contact but rather reside in the tumour stroma. New insights into the migration of NK cells, their activation status and production of matrix-degrading proteases might help to overcome this localization defect, with implications for the treatment of human cancer.
引用
收藏
页码:603 / 609
页数:7
相关论文
共 81 条
  • [71] Vujanovic Nikola L., 1996, Methods (Orlando), V9, P394, DOI 10.1006/meth.1996.0044
  • [72] Immunotherapy: past, present and future
    Waldmann, TA
    [J]. NATURE MEDICINE, 2003, 9 (03) : 269 - 277
  • [73] CTL: Caspases Terminate Life, but that's not the whole story
    Waterhouse, NJ
    Trapani, JA
    [J]. TISSUE ANTIGENS, 2002, 59 (03): : 175 - 183
  • [74] THE USE OF INTERLEUKIN-2 AND LYMPHOKINE-ACTIVATED KILLER-CELLS FOR THE TREATMENT OF PATIENTS WITH NON-HODGKINS-LYMPHOMA
    WEBER, JS
    YANG, JC
    TOPALIAN, SL
    SCHWARTZENTRUBER, DJ
    WHITE, DE
    ROSENBERG, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 33 - 40
  • [75] NATURAL-KILLER ACTIVITY OF LYMPHOCYTIC INFILTRATES IN MOUSE MAMMARY LESIONS
    WEI, WZ
    HEPPNER, G
    [J]. BRITISH JOURNAL OF CANCER, 1987, 55 (06) : 589 - 594
  • [76] Wiedle G, 1999, CANCER RES, V59, P5255
  • [77] ADAM family proteins in the immune system
    Yamamoto, S
    Higuchi, Y
    Yoshiyama, K
    Shimizu, E
    Kataoka, M
    Hijiya, N
    Matsuura, K
    [J]. IMMUNOLOGY TODAY, 1999, 20 (06): : 278 - 284
  • [78] Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases
    Yang, Q
    Hokland, ME
    Bryant, JL
    Zhang, YQ
    Nannmark, U
    Watkins, SC
    Goldfarb, RH
    Herberman, RB
    Basse, PH
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 105 (04) : 512 - 519
  • [79] Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
    Yao, L
    Sgadari, C
    Furuke, K
    Bloom, ET
    Teruya-Feldstein, J
    Tosato, G
    [J]. BLOOD, 1999, 93 (05) : 1612 - 1621
  • [80] Influence of cell cycling and cell division on transendothelial migration of CD34+ cells
    Yong, KL
    Fahey, A
    Pizzey, A
    Linch, DC
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) : 500 - 509